Infinity Pharmaceuticals Inc. (NASDAQ:INFI) has been given an average rating of “Hold” by the ten ratings firms that are covering the firm. Nine equities research analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $1.50.

A number of equities research analysts have commented on the stock. Wedbush restated a “neutral” rating and issued a $1.00 price target (down from $1.25) on shares of Infinity Pharmaceuticals in a report on Tuesday, August 9th. Morgan Stanley restated a “hold” rating and issued a $1.00 price target on shares of Infinity Pharmaceuticals in a report on Thursday, August 11th. Zacks Investment Research upgraded shares of Infinity Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.50 price target for the company in a report on Tuesday, October 18th. JPMorgan Chase & Co. restated a “hold” rating on shares of Infinity Pharmaceuticals in a report on Thursday, November 10th. Finally, FBR & Co restated a “hold” rating on shares of Infinity Pharmaceuticals in a report on Wednesday, August 10th.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD boosted its position in Infinity Pharmaceuticals by 156.7% in the third quarter. Price T Rowe Associates Inc. MD now owns 283,960 shares of the company’s stock valued at $443,000 after buying an additional 173,360 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its position in Infinity Pharmaceuticals by 6.7% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 694,875 shares of the company’s stock valued at $1,084,000 after buying an additional 43,600 shares during the period. Baker BROS. Advisors LP purchased a new position in Infinity Pharmaceuticals during the third quarter valued at $905,000. D. E. Shaw & Co. Inc. boosted its position in Infinity Pharmaceuticals by 6.6% in the third quarter. D. E. Shaw & Co. Inc. now owns 243,767 shares of the company’s stock valued at $381,000 after buying an additional 15,152 shares during the period. Finally, Northern Trust Corp boosted its position in Infinity Pharmaceuticals by 8.5% in the third quarter. Northern Trust Corp now owns 770,632 shares of the company’s stock valued at $1,202,000 after buying an additional 60,312 shares during the period. Institutional investors and hedge funds own 78.98% of the company’s stock.

Shares of Infinity Pharmaceuticals (NASDAQ:INFI) opened at 1.15 on Thursday. Infinity Pharmaceuticals has a 52 week low of $0.84 and a 52 week high of $8.98. The firm has a 50 day moving average price of $1.30 and a 200-day moving average price of $2.12. The firm’s market capitalization is $57.19 million.

Infinity Pharmaceuticals (NASDAQ:INFI) last posted its quarterly earnings results on Wednesday, November 9th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.47. Infinity Pharmaceuticals had a net margin of 13.23% and a negative return on equity of 125.20%. During the same period in the previous year, the business earned $0.84 earnings per share. Equities research analysts predict that Infinity Pharmaceuticals will post ($0.69) EPS for the current fiscal year.

Infinity Pharmaceuticals Company Profile

Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.

5 Day Chart for NASDAQ:INFI

Receive News & Stock Ratings for Infinity Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.